Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema shot shows promise in early trial

NCT ID NCT07488065

Recruiting now Symptom relief Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Mar 30, 2026 · Last updated Apr 25, 2026 · Updated 4 times

Summary

This early-stage study tests a new medicine called SKB575 in 90 people, first in healthy volunteers and then in those with moderate-to-severe atopic dermatitis (eczema). The main goals are to check safety and see if it can reduce eczema symptoms like redness and itching. Participants are randomly assigned to receive the drug or a placebo, and neither they nor the doctors know who gets what.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huashan Hospital Affiliated to Fudan University

    RECRUITING

    Shanghai, 200040, China

  • Huashan Hospital Affiliated to Fudan University

    RECRUITING

    Shanghai, 200040, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS